# KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

Source: https://onco.cc/trials/nct07406633/  
OnCo record `nct07406633` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Imatinib in metastatic cancer, run by Kumquat Biosciences Inc., now recruiting.

## Summary

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) is a phase 2 interventional study registered as NCT07406633 by Kumquat Biosciences Inc., with 46 participants planned, started 2026-06-23 and due to reach its primary completion in 2027-10. Interventions recorded: KQB198, Imatinib (Gleevec). Conditions listed: GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07406633
- Phase: 2
- Setting: A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
- Sponsor: Kumquat Biosciences Inc.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07406633: https://clinicaltrials.gov/study/NCT07406633

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/)
- companies: [Kumquat Biosciences](https://onco.cc/companies/kumquat-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07406633.json